Carcinotech manufactures 3D-printed micro-tumors using patient-derived biopsies, primary cells, immune cells, and cancer stem cells. Our advanced offering provides a platform for rapid, ethical, and accurate drug screening, pre-clinical, and personalized medicine testing. Carcinotech’s goal is to accelerate drug screening and enable the delivery of more effective cancer treatments to market. Using patient biopsies, tissue engineering, advanced robotic manufacturing, and quality control to produce highly predictive, assay-ready printed tumors at significant throughput. This provides our clients with a “clinical biopsy” quality model, using isolated patient-specific cells and representing donor-specific cancer heterogeneity.